ROCKLATAN(netarsudil and latanoprost ophthalmic solution)0.02%/0.005%, for topical ophthalmic(七)
solution. Seriousdamage to the eye and subsequent loss of vision may result from using contaminated solutions[see Warnings and Precautions (5.6)].
When to Seek Physician Advice
Advise patients that if they develop an intercurrent ocular condition (e.g., trauma or infection), have ocularsurgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they shouldimmediately seek their physician’s advice concerning the continued use of ROCKLATAN.
Use with Contact Lenses
Advise patients that ROCKLATAN contains benzalkonium chloride, which may be absorbed by sofcontact lenses. Contact lenses should be removed prior to instillation of ROCKLATAN and may bereinserted 15 minutes following its administration.
Use with Other Ophthalmic Drugs
If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutesbetween applications.
Missed Dose
Advise patients that if one dose is missed, treatment should continue with the next dose in the evening.
U.S. Patent Nos.: 8,450,344; 8,394,826; 9,096,569; 9,415,043; 9,931,336; 9,993,470ROCKLATAN is a trademark of Aerie Pharmaceuticals, Inc.
Manufactured for: Aerie Pharmaceuticals, Inc., Irvine, CA 92614, U.S.A.
http://investors.aeriepharma.com/static-files/8afba638-3210-4a9a-913b-558d7b7dfc7b |
